Press Releases

Investor Alerts

Aug 11, 2020

Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020
Aug 6, 2020

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101

ASCEND results expected to support STS101 NDA filing in Q4 2021
Jul 7, 2020

Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors
Jun 11, 2020

Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting hosted via a Virtual Meeting Platform

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)
Jun 1, 2020

Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine

More than 1,140 patients randomized and topline results expected in second half 2020

Show per page